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“I don’t expect to get yesterday’s medicine. If I 
can help it, I’ d like to get tomorrow’s medicine.”
– Elizabeth Edwards
Glioblastoma (GBM) is the most preva-
lent and aggressive malignant brain tumor 
with a median survival from diagnosis of 
12–15 months. Standard-of-care treatment 
consists of radical surgery followed by radio-
therapy with concomitant systemic temo-
zolomide. Nevertheless, due to the infiltrative 
nature of GBM, this treatment strategy almost 
universally fails to eradicate minimal volume 
residual disease, which typically recurs within 
2 cm from the original lesion [1]. A homoge-
neous treatment regime and regrowth of the 
tumor locally present a firm clinical and sci-
entific rationale in which to develop innova-
tive therapies delivered interstitially. There 
is a critical need to develop more effective 
and targeted chemotherapy regimes that can 
eradicate residual GBM cells following neu-
rosurgical resection, thereby improving local 
control within the brain parenchyma beyond 
the surgical cavity wall and reducing the risk 
of tumor recurrence [2]. The opportunity to 
deliver therapeutic cancer drug concentra-
tions locally creates the possibility of improv-
ing both the safety (low toxic dose systemi-
cally) and efficacy (high effective dose locally) 
of cancer chemotherapy, thereby enhancing 
the benefit of surgery, as well as continuing 
antineoplastic treatment during the inter-
val between surgery and commencement of 
systemic adjuvant therapy.
Although a myriad of drug-polymer devices 
have been developed to date, the Food and 
Drug Administration and National Institute 
for Health and Clinical Excellence has solely 
approved the use of chemotherapy impreg-
nated polymeric wafers (Gliadel®) for local 
chemotherapy delivered via a biomaterial, for 
the treatment of primary and recurrent malig-
nant glioma. These wafers which are neurosur-
gically implanted at the time of tumor resec-
tion, gradually release the chemotherapeutic 
agent carmustine, which then diffuses into 
the surrounding brain and targets the residual 
cancer cells that have infiltrated the brain tis-
sue. These studies and trials offer hope to this 
mode of intracavity drug delivery, with results 
showing a moderate but significant survival 
benefit of 2.3 months and 1.8 months median 
survival for newly diagnosed and recurrent 
high-grade gliomas, respectively [3,4]. The 
treatment has nevertheless shown limited effi-
cacy mainly due to: (i) poor drug diffusion, 
restricted to 2–3-mm bordering the implant; 
(ii) implants not maintaining close contact 
with the resection cavity rim and falling to the 
bottom of the cavity; (iii) only one drug being 
delivered [5]. OncoGel™, a controlled-release 
formulation of paclitaxel in ReGel™, com-
prising a thermosensitive triblock copolymer 
(PLGA-PEG-PLGA), has shown much pre-
clinical promise. This system is water soluble 
at 2–15°C and turns into a viscous gel at body 
temperature [6]. Preclinical and early clinical 
investigations demonstrated OncoGel™’s 
ability to physically target paclitaxel to brain 
tumor tissue via intralesional injection into 
the tumor cavity following resection, with an 
acceptable safety profile and moderate increase 
in survival in a rat gliosarcoma model [7].
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Our partners at the School of Pharmacy, University 
of Nottingham, have developed a novel formulation of 
PLGA/PEG copolymer microparticles which creates a 
moldable paste when mixed with liquid. At body tem-
perature only, the paste hardens into a solid matrix, 
potentially releasing multiple drugs simultaneously 
over several weeks. We have previously described this 
PLGA/PEG formulation as the only drug-delivery for-
mulation to our knowledge that can be pasted onto the 
tumor resection cavity wall, thereby potentially offer-
ing closer proximity of drug depot to residual tumor 
cells than existing methods. The material has clear 
clinical utility as we have demonstrated the relative 
ease of application ex vivo, distinguished the bioma-
terial on MRI/CT clinical scans and shown that the 
material can withstand a 6-week clinically relevant 
radiotherapy dosing schedule [8].
The rationale of these polymer-based approaches is 
to improve upon drug efficacy, increase exposure time 
of tumor cells to drug, protect drugs from degradation 
and clearance by the immune system until its release 
from the polymer and reduce the debilitating sequels 
of current systemic chemotherapeutics, allowing onco-
logical treatment to be maintained in the interval 
between surgery and radiotherapy.
However, it is not clear whether the failure of che-
motherapy drugs to achieve durable responses in GBM 
is due to the intrinsic resistance of residual disease or 
the lack of drug penetration at therapeutic doses. The 
former can realistically only be overcome using next-
generation molecularly targeted chemotherapeutics, 
whereas the latter is a considerable obstacle for more 
efficacious drug delivery in the future. However, given 
the difficulty associated with measuring chemothera-
peutic drug distribution in the central nervous sys-
tem, tissue-based pharmacokinetic measurements are 
typically not achievable in human clinical settings. 
Therefore, drug distribution has been measured in 
the brains of rodents and nonhuman primates as sur-
rogate models to advance drug selection for the treat-
ment of brain tumors. Such approaches rely on high 
numbers of animals and cannot address how nonla-
beled native drugs released from a local delivery sys-
tem behave when diffusing throughout brain tissues. 
Technologies that utilize mass spectrometry (MS) as 
a detector for diverse analytes could potentially over-
come some of these limitations, by directly measuring 
individual molecular species in complex samples. One 
such method is liquid extraction surface analysis MS 
(LESA–MS), a novel ambient surface profiling tech-
nique that combines liquid extraction of analytes from 
a solid surface (e.g., organ-specific tissue) with nano-
electrospray MS [9,10]. The distribution of drugs could 
thus be characterized rapidly by analyzing anatomical 
contexts ex vivo, such as brain-slice cultures, where the 
delivery system can be incorporated. LESA–MS pres-
ents added benefits including the ability to discrimi-
nate multiple drugs simultaneously, lower costs, little-
to-no sample preparation, rapid analysis and analysis 
in an ambient environment – features important for 
effective spatially-resolved drug localization.
Drug delivery using a single local administration 
requires careful consideration of potential damage to 
healthy neural cells. Understanding drug distribu-
tion from the polymer is crucial to predict the effect 
on tumor cells and normal brain. One difficulty is 
that therapeutic doses and maximum tolerated doses 
typically relate to systemic delivery. To overcome this 
we anticipate loading drug amounts in our polymer 
system based on drug release data from in vitro and 
in vivo studies, ensuring that the early burst release is 
less than the maximum tolerated doses. Selection of 
locally delivered chemotherapeutic agents that display 
widespread brain tissue distribution will benefit brain 
tumor patients by potentially offering more effica-
cious treatment directly at the site of the tumor.
As we progress towards an era of individualized 
medicine, equipped to target specific molecules and 
pathways in GBM and other brain tumors, we need 
to continue to develop local drug-delivery systems 
as a crucial corollary. Drug-delivery innovations will 
enable us to expand the selection of chemotherapeu-
tics that will become amenable for use in the clinic, 
ultimately to the benefit of the patients and their 
families.
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